Hokum North America Box Office: Earns $2.6 Million On Opening Day – How It Compares To 2026’s Top 5 Highest-Grossing Horror Films

Why It Matters

Hokum’s strong critical buzz paired with modest earnings shows that well‑received, lower‑budget horror can still capture audience dollars, influencing studio release strategies. It underscores the importance of word‑of‑mouth for sustaining box‑office momentum beyond opening day.

Key Takeaways

• Hokum earned $2.6 M on its opening day in North America.
• Opening day is far below Scream 7’s $29.4 M debut.
• 86% Rotten Tomatoes score suggests strong critical reception.
• Projected domestic total around $15 M using 5.6× multiplier.
• Mid‑budget horror can achieve solid returns without franchise backing.

Pulse Analysis

2026 has emerged as a banner year for horror, with seven titles cracking the domestic top‑20 and the genre accounting for a sizable share of box‑office receipts. Blockbusters like Scream 7 ($121.9 M total) and Sam Raimi’s Send Help ($64.7 M) dominate the leaderboard, but the market also rewards leaner productions that tap into audience cravings for fresh scares. Against this backdrop, the supernatural thriller Hokum entered the scene, leveraging star power from Adam Scott and a strong Rotten Tomatoes consensus to generate a $2.6 million opening day.

While Hokum’s debut pales in comparison to the $29.4 million opening of Scream 7, its performance aligns more closely with the modest horror tier. The film’s 86% critic score signals quality that could translate into sustained ticket sales, a pattern observed with Primate, which opened at $4.6 million and ultimately earned $25.6 million—a 5.6× domestic multiplier. Applying the same multiplier to Hokum yields a projected $15 million total, a respectable figure for a mid‑budget title. This estimate hinges on positive word‑of‑mouth and steady weekend holds, factors that historically amplify horror earnings beyond the first weekend.

The broader implication for studios is clear: critical acclaim can offset the lack of franchise branding, especially in a genre where audience loyalty is driven by novelty and scare factor. Distributors may prioritize strategic release windows, targeted marketing, and early critic screenings to maximize buzz. If Hokum sustains its momentum, it could reinforce the business case for investing in original horror concepts, encouraging a diversified slate that balances tentpole sequels with inventive, lower‑budget offerings.